Ann: INCREASED LACTOFERRIN RANGE SALES DUE TO CORONAVIRUS, page-225

I'd be interested in what you've listed, plus:
- a well put together investor presentation to go along with the media campaign,
- an explanation / clarification on the dividend payment in the quarterly, so it is clear one way or another,
- an update on their debt funding, as there's significant exposure there,
- announcements providing updates on the agreements, such as Ocker, in terms of actual sales volumes (as much as I like what they've achieved, pretty much every agreement is non-binding to some extent, so it would be good to hear actual status),
- consolidation of the share registry being back on the table, potentially subject to SP/MC movement,
- an update on the Shanghai store and any plans for further stores

With the additional ANMA lines coming on board I wouldn't think it's appropriate for a 2nd facility yet as the dust hasn't settled on this. As mentioned, we have orders with only tacit commitment to buy. If there's proven sustained volume that ANMA is unable to meet, then by all means another facility could come into the frame.